The Filing Desk

BeOne Medicines

ONC · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ONC · Last close · November 19, 2026
$399.70
Value BeOne Medicines yourself

BeOne Medicines' revenue rose 40.2% to $5.3 billion in fiscal 2025. Its operating margin was 8.4%, up from −14.9% a year earlier. Free cash flow was $942 million. The diluted share count rose 7.8%.

BEONE MEDICINES LTD. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001628280-26-011946 Updated
Revenue
$5.3B
40.2%
Operating margin
8.4%
23.3 pts
Net income
$287M
 
Free cash flow
$942M
 
Return on capital
25.8%
56.0 pts
Market cap
$609.5B
Nov 19 close
P/E
—
Over 200x

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments6,6184,5353,1742,6274,548
Debt incl. finance leases—5388861,018845
Net debt (negative means net cash)—−3,997−2,288−1,609−3,702
Net debt to EBITDA————−6.3x
Debt to equity—0.1x0.2x0.3x0.2x
Interest coverage−49.2x−82.5x−276.8x−26.1x7.7x
Current ratio4.8x3.5x2.3x1.8x3.4x
Quick ratio4.6x3.4x2.1x1.6x3.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, billions

Projections

Project BeOne Medicines' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought BeOne Medicines shares on the open market, and 12 insiders sold $361.1 million, $351.9 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 28, 2026Xiaodong WangDirectorSold plan31,028$364.79$11.3 millionForm 4
Sep 8, 2026Xiaodong WangDirectorSold plan38,287$349.10$13.4 millionForm 4
Sep 1, 2026Titus B. BallPrincipal Accounting OfficerSold132$355.86$46,974Form 4
Aug 25, 2026Xiaobin WuPresident and COOSold plan280$380.00$106,400Form 4
Aug 12, 2026John OylerChief Executive Officer, DirectorSold plan54,892$358.15$19.7 millionForm 4
Aug 11, 2026John OylerChief Executive Officer, DirectorSold plan70,907$361.90$25.7 millionForm 4
Aug 11, 2026Chan Henry LeeSVP, General CounselSold plan2,666$360.00$959,760Form 4
Aug 10, 2026John OylerChief Executive Officer, DirectorSold plan115,011$357.88$41.2 millionForm 4
Aug 3, 2026Aaron RosenbergChief Financial OfficerSold1,157$312.72$361,817Form 4
Jul 30, 2026Chan Henry LeeSVP, General CounselSold1,044$323.69$337,932Form 4
Jul 22, 2026Chan Henry LeeSVP, General CounselSold plan1,669$325.00$542,425Form 4
Jul 21, 2026John OylerChief Executive Officer, DirectorSold plan61,397$317.67$19.5 millionForm 4
The latest 12 of 53 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 93 of 98 of 9
Rule of 403.7%38.3%57.9%
Altman Z''−1.53−2.061.78
Accruals ratio4.5%−8.6%−11.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsFailFailPass
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rosePassFailPass
Revenue rose relative to assetsPassPassPass
F-score3 of 93 of 98 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put BeOne Medicines side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
BeOne MedicinesFY2540.2%8.4%17.6%25.8%−6.3x8
ElancoFY256.2%—6.0%−0.1%5.2x6Compare
OrganonFY25−2.9%—8.7%5.3%6.3x5Compare
Jazz PharmaceuticalsFY254.9%−10.1%30.4%−4.2%—4Compare
PerrigoFY25−2.8%−26.4%3.4%−13.2%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue12381984283091,1761,4162,4593,8105,343
Revenue growth−87.9%22,179.2%−16.9%116.0%−27.9%280.8%20.4%73.7%55.0%40.2%
Gross profit12331703572381,0111,1292,0793,2164,674
Research and development982696799271,2951,4591,6401,7791,9532,146
Operating income−117−98−706−960−1,658−1,439−1,790−1,208−568447
Net income−119−93−674−949−1,625−1,458−2,004−882−645287
Diluted EPS (US$)−0.30−0.17−0.93−1.22−1.50−1.21−1.49−0.65−0.470.19
Diluted shares (millions)4045437217811,0851,2061,3411,3571,3691,475
Cash flow
Cash from operations−9013−548−750−1,284−1,299−1,497−1,158−1411,128
Capital expenditure24467090118263325562493186
Free cash flow−113−34−618−840−1,401−1,562−1,822−1,719−633942
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation114387134184241303368442511
Balance sheet at fiscal year end
Cash and short-term investments3688381,7819834,6516,6184,5353,1742,6274,548
Debt incl. finance leases—185083854—5388861,018845
Total assets4061,0462,2501,6125,6018,5366,3795,8055,9218,189
Total liabilities533624966341,7322,4031,9962,2682,5893,827
Shareholders' equity3536701,7399623,8696,1334,3833,5373,3324,361
Margins and ratios
Gross margin100.0%97.9%85.5%83.4%77.1%86.0%79.8%84.5%84.4%87.5%
Operating margin−10,940.2%−41.3%−356.1%−224.2%−536.7%−122.3%−126.4%−49.1%−14.9%8.4%
Net margin−11,141.8%−39.1%−339.9%−221.5%−526.1%−123.9%−141.5%−35.9%−16.9%5.4%
Free cash flow margin−10,562.1%−14.1%−311.8%−196.1%−453.6%−132.8%−128.7%−69.9%−16.6%17.6%
Rule of 40 (growth + FCF margin)−10,650.0%22,165.0%−328.6%−80.1%−481.4%148.1%−108.3%3.7%38.3%57.9%
Return on capital———————−116.7%−30.2%25.8%
Return on equity−94.9%−18.2%−55.9%−70.2%−67.3%−29.1%−38.1%−22.3%−18.8%7.5%
Return on assets−45.6%−12.8%−40.9%−49.1%−45.1%−20.6%−26.9%−14.5%−11.0%4.1%
Net debt to EBITDA—————————−6.3x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: BeOne Medicines' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with BeOne Medicines.